$PBLA a lot of times after the r/s companies announce some nice news $PALI for example and it’s news of expedited fda … glad to see it coming riding into the r/s sunset

Come april it will bounce nicely for 30% plus minus 5% IF fda approves.

$PALI FDA fast track $25 easy

$PALI you will not get cheaper than this 🔥 FDA already fast track the GI drug 🚨

FDA Fast Track Designation is gold.

$ARDX I am thrilled that the chairwoman of our Adcom gave monotherapy a thumbs up.

This is 100% normal and part of the growth of a strong company with excellent fundamentals and an FDA approval coming this year.

Better than money in the bank with soon resubmission and approval 2-6 months later!

So glad that I bought before ADCOM meeting.

$ARDX very good fda news on this conference call

And this is just a beginning, FDA approval will take it to the skies.

Pretty Bullish ER going to give us an update on FDA when and etc. .

If the trend of script numbers is anything to go by, guidance could be way better than Wall Street expects giving us a nice boost before FDA news.

$AKBA within 3 to 4 weeks this stock could be over 2 heading to three like $ARDX .. gsk approval has helped.. fda news, ema opinion/ approval, partnership..

$ARDX This company is sitting on a mountain of great fundamentals.. 40++ medical patents ,,, 40+ more in application status 1 drug approved IBSRELA 1 drug almost aproved XPHOZAH a kidney drug that could pull an annual billion dollar + revenue.

$BLUE perfect timing for our BLA submission upcoming! !

$BLUE The most positive news is it’s one day closer to the earnings release and one day closer to the BLA submission plus this is currently a rare day where this is beating out the XBI and LABU by not being down as much.

Confidence of FDA approval for lovo-cel is valid and the balance sheet is sound.

$BLUE Favorite part of today’s update were the words, ” clear path to submission“ For Lovo-cel ” This quarter”.

Fast Track- More frequent meetings with FDA.

To further make investors happy, the companies time line and submission for lovo cel are as promised!!

$BLUE FDA news is pretty bullish

$BLUE Cash runway solid, two recent FDA approvals, and leading the pack with SCD.

Data from today looked promising, cash flow seems to be sorred it (for now), and already 2 FDA approvals working on 3.

$BLUE One more milestone - go ahead with Q1 SCD BLA submission - and this is the best value in all of biotech.